DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury

Jianyi Wang, Qing Ye, Jing Xu, Gil Benedek, Haiyue Zhang, Yuanyuan Yang, Huan Liu, Roberto Meza-Romero, Arthur Vandenbark, Halina Offner, Yanqin Gao

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Stroke induces a catastrophic immune response that involves the global activation of peripheral leukocytes, especially T cells. The human leukocyte antigen-DRα1 domain linked to MOG-35-55 peptide (DRα1-MOG-35-55) is a partial major histocompatibility complex (MHC) class II construct which can inhibit neuroantigen-specific T cells and block binding of the cytokine/chemokine macrophage migration inhibitory factor (MIF) to its CD74 receptor on monocytes and macrophages. Here, we evaluated the therapeutic effect of DRα1-MOG-35-55 in a mouse model of permanent distal middle cerebral artery occlusion (dMCAO). DRα1-MOG-35-55 was administered to WT C57BL/6 mice by subcutaneous injection starting 4 h after the onset of ischemia followed by three daily injections. We demonstrated that DRα1-MOG-35-55 post treatment significantly reduced brain infarct volume, improved functional outcomes, and inhibited the accumulation of CD4+ and CD8+ T cells and expression of pro-inflammatory cytokines in the ischemic brain 96 h after dMCAO. In addition, DRα1-MOG-35-55 treatment shifted microglia/macrophages in the ischemic brain to a beneficial M2 phenotype without changing their total numbers in the brain or blood. This study demonstrates for the first time the therapeutic efficacy of the DRα1-MOG-35-55 construct in dMCAO across MHC class II barriers in C57BL/6 mice. This MHC-independent effect obviates the need for tissue typing and will thus greatly expedite treatment with DRα1-MOG-35-55 in human stroke subjects. Taken together, our findings suggest that DRα1-MOG-35-55 treatment may reduce ischemic brain injury by regulating post-stroke immune responses in the brain and the periphery.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalTranslational Stroke Research
DOIs
StateAccepted/In press - Dec 17 2016

Fingerprint

Brain Injuries
Middle Cerebral Artery Infarction
Major Histocompatibility Complex
Brain
Stroke
T-Lymphocytes
Inbred C57BL Mouse
Macrophages
Cytokines
Macrophage Migration-Inhibitory Factors
Therapeutics
Histocompatibility Testing
Microglia
Therapeutic Uses
Subcutaneous Injections
HLA Antigens
Chemokines
Monocytes
Leukocytes
Ischemia

Keywords

  • DRα1-MOG-35-55
  • Inflammation
  • Microglia/macrophage
  • Stroke
  • T lymphocytes

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Wang, J., Ye, Q., Xu, J., Benedek, G., Zhang, H., Yang, Y., ... Gao, Y. (Accepted/In press). DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury. Translational Stroke Research, 1-10. https://doi.org/10.1007/s12975-016-0514-2

DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury. / Wang, Jianyi; Ye, Qing; Xu, Jing; Benedek, Gil; Zhang, Haiyue; Yang, Yuanyuan; Liu, Huan; Meza-Romero, Roberto; Vandenbark, Arthur; Offner, Halina; Gao, Yanqin.

In: Translational Stroke Research, 17.12.2016, p. 1-10.

Research output: Contribution to journalArticle

Wang, J, Ye, Q, Xu, J, Benedek, G, Zhang, H, Yang, Y, Liu, H, Meza-Romero, R, Vandenbark, A, Offner, H & Gao, Y 2016, 'DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury', Translational Stroke Research, pp. 1-10. https://doi.org/10.1007/s12975-016-0514-2
Wang, Jianyi ; Ye, Qing ; Xu, Jing ; Benedek, Gil ; Zhang, Haiyue ; Yang, Yuanyuan ; Liu, Huan ; Meza-Romero, Roberto ; Vandenbark, Arthur ; Offner, Halina ; Gao, Yanqin. / DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury. In: Translational Stroke Research. 2016 ; pp. 1-10.
@article{3cc17aefb5d744f7802bcb05c5bffcab,
title = "DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury",
abstract = "Stroke induces a catastrophic immune response that involves the global activation of peripheral leukocytes, especially T cells. The human leukocyte antigen-DRα1 domain linked to MOG-35-55 peptide (DRα1-MOG-35-55) is a partial major histocompatibility complex (MHC) class II construct which can inhibit neuroantigen-specific T cells and block binding of the cytokine/chemokine macrophage migration inhibitory factor (MIF) to its CD74 receptor on monocytes and macrophages. Here, we evaluated the therapeutic effect of DRα1-MOG-35-55 in a mouse model of permanent distal middle cerebral artery occlusion (dMCAO). DRα1-MOG-35-55 was administered to WT C57BL/6 mice by subcutaneous injection starting 4 h after the onset of ischemia followed by three daily injections. We demonstrated that DRα1-MOG-35-55 post treatment significantly reduced brain infarct volume, improved functional outcomes, and inhibited the accumulation of CD4+ and CD8+ T cells and expression of pro-inflammatory cytokines in the ischemic brain 96 h after dMCAO. In addition, DRα1-MOG-35-55 treatment shifted microglia/macrophages in the ischemic brain to a beneficial M2 phenotype without changing their total numbers in the brain or blood. This study demonstrates for the first time the therapeutic efficacy of the DRα1-MOG-35-55 construct in dMCAO across MHC class II barriers in C57BL/6 mice. This MHC-independent effect obviates the need for tissue typing and will thus greatly expedite treatment with DRα1-MOG-35-55 in human stroke subjects. Taken together, our findings suggest that DRα1-MOG-35-55 treatment may reduce ischemic brain injury by regulating post-stroke immune responses in the brain and the periphery.",
keywords = "DRα1-MOG-35-55, Inflammation, Microglia/macrophage, Stroke, T lymphocytes",
author = "Jianyi Wang and Qing Ye and Jing Xu and Gil Benedek and Haiyue Zhang and Yuanyuan Yang and Huan Liu and Roberto Meza-Romero and Arthur Vandenbark and Halina Offner and Yanqin Gao",
year = "2016",
month = "12",
day = "17",
doi = "10.1007/s12975-016-0514-2",
language = "English (US)",
pages = "1--10",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",

}

TY - JOUR

T1 - DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury

AU - Wang, Jianyi

AU - Ye, Qing

AU - Xu, Jing

AU - Benedek, Gil

AU - Zhang, Haiyue

AU - Yang, Yuanyuan

AU - Liu, Huan

AU - Meza-Romero, Roberto

AU - Vandenbark, Arthur

AU - Offner, Halina

AU - Gao, Yanqin

PY - 2016/12/17

Y1 - 2016/12/17

N2 - Stroke induces a catastrophic immune response that involves the global activation of peripheral leukocytes, especially T cells. The human leukocyte antigen-DRα1 domain linked to MOG-35-55 peptide (DRα1-MOG-35-55) is a partial major histocompatibility complex (MHC) class II construct which can inhibit neuroantigen-specific T cells and block binding of the cytokine/chemokine macrophage migration inhibitory factor (MIF) to its CD74 receptor on monocytes and macrophages. Here, we evaluated the therapeutic effect of DRα1-MOG-35-55 in a mouse model of permanent distal middle cerebral artery occlusion (dMCAO). DRα1-MOG-35-55 was administered to WT C57BL/6 mice by subcutaneous injection starting 4 h after the onset of ischemia followed by three daily injections. We demonstrated that DRα1-MOG-35-55 post treatment significantly reduced brain infarct volume, improved functional outcomes, and inhibited the accumulation of CD4+ and CD8+ T cells and expression of pro-inflammatory cytokines in the ischemic brain 96 h after dMCAO. In addition, DRα1-MOG-35-55 treatment shifted microglia/macrophages in the ischemic brain to a beneficial M2 phenotype without changing their total numbers in the brain or blood. This study demonstrates for the first time the therapeutic efficacy of the DRα1-MOG-35-55 construct in dMCAO across MHC class II barriers in C57BL/6 mice. This MHC-independent effect obviates the need for tissue typing and will thus greatly expedite treatment with DRα1-MOG-35-55 in human stroke subjects. Taken together, our findings suggest that DRα1-MOG-35-55 treatment may reduce ischemic brain injury by regulating post-stroke immune responses in the brain and the periphery.

AB - Stroke induces a catastrophic immune response that involves the global activation of peripheral leukocytes, especially T cells. The human leukocyte antigen-DRα1 domain linked to MOG-35-55 peptide (DRα1-MOG-35-55) is a partial major histocompatibility complex (MHC) class II construct which can inhibit neuroantigen-specific T cells and block binding of the cytokine/chemokine macrophage migration inhibitory factor (MIF) to its CD74 receptor on monocytes and macrophages. Here, we evaluated the therapeutic effect of DRα1-MOG-35-55 in a mouse model of permanent distal middle cerebral artery occlusion (dMCAO). DRα1-MOG-35-55 was administered to WT C57BL/6 mice by subcutaneous injection starting 4 h after the onset of ischemia followed by three daily injections. We demonstrated that DRα1-MOG-35-55 post treatment significantly reduced brain infarct volume, improved functional outcomes, and inhibited the accumulation of CD4+ and CD8+ T cells and expression of pro-inflammatory cytokines in the ischemic brain 96 h after dMCAO. In addition, DRα1-MOG-35-55 treatment shifted microglia/macrophages in the ischemic brain to a beneficial M2 phenotype without changing their total numbers in the brain or blood. This study demonstrates for the first time the therapeutic efficacy of the DRα1-MOG-35-55 construct in dMCAO across MHC class II barriers in C57BL/6 mice. This MHC-independent effect obviates the need for tissue typing and will thus greatly expedite treatment with DRα1-MOG-35-55 in human stroke subjects. Taken together, our findings suggest that DRα1-MOG-35-55 treatment may reduce ischemic brain injury by regulating post-stroke immune responses in the brain and the periphery.

KW - DRα1-MOG-35-55

KW - Inflammation

KW - Microglia/macrophage

KW - Stroke

KW - T lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85006365068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006365068&partnerID=8YFLogxK

U2 - 10.1007/s12975-016-0514-2

DO - 10.1007/s12975-016-0514-2

M3 - Article

SP - 1

EP - 10

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

ER -